Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-controlled, Double Blind, Single Ascending and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients
Conditions
Interventions
FT-4202/Placebo
Locations
18
United States
Woodland International Research Group (SCD subjects only)
Little Rock, Arkansas, United States
Collaborative Neuroscience Research, LLC (SCD subjects only)
Long Beach, California, United States
Pacific Research Partners (SCD subjects only)
Oakland, California, United States
UCSF Benioff Children's Hospital Oakland (SCD subjects only)
Oakland, California, United States
Advanced Pharma CR, LLC (SCD subjects only)
Miami, Florida, United States
Children's Healthcare of Atlanta (SCD subjects only)
Atlanta, Georgia, United States
Start Date
December 11, 2018
Primary Completion Date
December 17, 2021
Completion Date
December 17, 2021
Last Updated
April 10, 2024
NCT07310264
NCT06342713
NCT07472361
NCT05170412
NCT06649110
NCT06823947
Lead Sponsor
Forma Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions